These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Long-term outcomes following the addition of granulocyte colony-stimulating factor-combined high-dose cytarabine to total body irradiation and cyclophosphamide conditioning in single-unit cord blood transplantation for myeloid malignancies. Konuma T; Ooi J; Nagayama H; Tomonari A; Tsukada N; Kato S; Kawakita T; Isobe M; Monna-Oiwa M; Tojo A; Iseki T; Takahashi S Ann Hematol; 2022 Jan; 101(1):177-189. PubMed ID: 34591162 [TBL] [Abstract][Full Text] [Related]
8. Reduced-Toxicity Myeloablative Conditioning Consisting of Fludarabine/Busulfan/Low-Dose Total Body Irradiation/Granulocyte Colony-Stimulating Factor-Combined Cytarabine in Single Cord Blood Transplantation for Elderly Patients with Nonremission Myeloid Malignancies. Konuma T; Kato S; Isobe M; Mizusawa M; Oiwa-Monna M; Takahashi S; Tojo A Biol Blood Marrow Transplant; 2019 Apr; 25(4):764-770. PubMed ID: 30529460 [TBL] [Abstract][Full Text] [Related]
9. Cord blood transplantation for acute myelogenous leukemia using a conditioning regimen consisting of granulocyte colony-stimulating factor-combined high-dose cytarabine, fludarabine, and total body irradiation. Tomonari A; Takahashi S; Ooi J; Nakaoka T; Takasugi K; Uchiyama M; Tsukada N; Konuma T; Iseki T; Tojo A; Asano S Eur J Haematol; 2006 Jul; 77(1):46-50. PubMed ID: 16573743 [TBL] [Abstract][Full Text] [Related]
10. Effects of priming with recombinant human granulocyte colony-stimulating factor on conditioning regimen for high-risk acute myeloid leukemia patients undergoing human leukocyte antigen-haploidentical hematopoietic stem cell transplantation: a multicenter randomized controlled study in southwest China. Gao L; Wen Q; Chen X; Liu Y; Zhang C; Gao L; Kong P; Zhang Y; Li Y; Liu J; Wang Q; Su Y; Wang C; Wang S; Zeng Y; Sun A; Du X; Zeng D; Liu H; Peng X; Zhang X Biol Blood Marrow Transplant; 2014 Dec; 20(12):1932-9. PubMed ID: 25109850 [TBL] [Abstract][Full Text] [Related]
11. Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia. Gyurkocza B; Gutman J; Nemecek ER; Bar M; Milano F; Ramakrishnan A; Scott B; Fang M; Wood B; Pagel JM; Baumgart J; Delaney C; Maziarz RT; Sandmaier BM; Estey EH; Appelbaum FR; Storer BE; Deeg HJ Biol Blood Marrow Transplant; 2014 Apr; 20(4):549-55. PubMed ID: 24440648 [TBL] [Abstract][Full Text] [Related]
12. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. Schmid C; Schleuning M; Ledderose G; Tischer J; Kolb HJ J Clin Oncol; 2005 Aug; 23(24):5675-87. PubMed ID: 16110027 [TBL] [Abstract][Full Text] [Related]
13. Prospective multicenter study of single-unit cord blood transplantation with myeloablative conditioning for adult patients with high-risk hematologic malignancies. Mori T; Tanaka M; Kobayashi T; Ohashi K; Fujisawa S; Yokota A; Fujita H; Nakaseko C; Sakura T; Nannya Y; Takahashi S; Kanamori H; Kanda Y; Sakamaki H; Okamoto S; Biol Blood Marrow Transplant; 2013 Mar; 19(3):486-91. PubMed ID: 23253560 [TBL] [Abstract][Full Text] [Related]
14. Hematopoietic stem cell transplantation in children and young adults with secondary myelodysplastic syndrome and acute myelogenous leukemia after aplastic anemia. Yoshimi A; Strahm B; Baumann I; Furlan I; Schwarz S; Teigler-Schlegel A; Walther JU; Schlegelberger B; Göhring G; Nöllke P; Führer M; Niemeyer CM Biol Blood Marrow Transplant; 2014 Mar; 20(3):425-9. PubMed ID: 24316460 [TBL] [Abstract][Full Text] [Related]
15. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival. Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801 [TBL] [Abstract][Full Text] [Related]
16. Feasible outcomes of T cell-replete haploidentical stem cell transplantation with reduced-intensity conditioning in patients with myelodysplastic syndrome. Shin SH; Kim JH; Jeon YW; Yoon JH; Yahng SA; Lee SE; Choi YS; Kim DY; Lee JH; Lee S; Kim HJ; Min CK; Lee JW; Lee KH; Min WS; Kim YJ; Lee JH Biol Blood Marrow Transplant; 2015 Feb; 21(2):342-9. PubMed ID: 25459640 [TBL] [Abstract][Full Text] [Related]
17. Risk factors before autologous stem-cell transplantation for lymphoma predict for secondary myelodysplasia and acute myelogenous leukemia. Kalaycio M; Rybicki L; Pohlman B; Sobecks R; Andresen S; Kuczkowski E; Bolwell B J Clin Oncol; 2006 Aug; 24(22):3604-10. PubMed ID: 16877727 [TBL] [Abstract][Full Text] [Related]
18. Fludarabine, cytarabine, granulocyte colony-stimulating factor and melphalan (FALG with L-PAM) as a reduced toxicity conditioning regimen in children with acute leukemia. Kato K; Yoshida N; Matsumoto K; Matsuyama T Pediatr Blood Cancer; 2014 Apr; 61(4):712-6. PubMed ID: 24376191 [TBL] [Abstract][Full Text] [Related]
19. Long-term remissions in patients with myelodysplastic syndrome and secondary acute myelogenous leukemia undergoing allogeneic transplantation following a reduced intensity conditioning regimen of 550 cGy total body irradiation and cyclophosphamide. Hallemeier CL; Girgis MD; Blum WG; Brown RA; Khoury HJ; Devine SM; Vij R; Lin HS; DiPersio JF; Adkins DR Biol Blood Marrow Transplant; 2006 Jul; 12(7):749-57. PubMed ID: 16785064 [TBL] [Abstract][Full Text] [Related]